# US 2022/0276259 A1 · Methods for diagnosing systemic lupus erythematosus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0276259 A1
- Document ID: US20220276259A1
- Status: Published application
- Kind: A1
- Application number: 17/743,289
- Filed: 2022-05-12
- Published: 2022-09-01
- Earliest claimed: 2011-02-11
- Assignees: Exagen Inc.
- Applicants: Exagen Inc.
- Inventors: Thierry Dervieux; Cole Harris
- Web page: https://patentgrep.com/patent/US20220276259A1

## CPC

- G01N 33/6854: {Immunoglobulins}
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 2800/104: Lupus erythematosus [SLE]
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus.

## Claims

### Claim 1

A method for treating systemic lupus erythematosus in a human subject in need thereof, the method comprising:
(a) measuring a level of erythrocyte-bound C4d (EC4d) marker, B-lymphocyte-bound C4d (BC4d) marker, and anti-nuclear antibody (ANA) in a blood sample obtained from the human subject;
(b) administering to the human subject an effective amount of cyclophosphamide, a corticosteroid, mycophenolate, methotrexate, azathioprine, leflunomide, belimumab, or hydroxychloroquine to treat systemic lupus erythematosus;
wherein the human subject is negative for systemic lupus erythematosus based on their level of double-stranded DNA.

### Claim 2 (depends on 1)

The method of claim 1, wherein the level of EC4d marker in the blood sample is measured with fluorescence-activated cell sorting.

### Claim 3 (depends on 1)

The method of claim 1, wherein the level of BC4d marker in the blood sample is measured with fluorescence-activated cell sorting.

### Claim 4 (depends on 1)

The method of claim 1, wherein the level of ANA in the blood sample is measured an enzyme-linked immunosorbent assay or fluorescence-activated cell sorting.

### Claim 5 (depends on 1)

The method of claim 1, wherein measuring the level of EC4d marker comprises measuring the level of EC4d on the surface of erythrocytes.

### Claim 6 (depends on 1)

The method of claim 1, wherein measuring the level of BC4d marker comprises measuring the level of BC4d on the surface of B lymphocytes.

### Claim 7 (depends on 1)

The method of claim 1, further comprising applying a transformation analysis to the level of EC4d marker, BC4d marker, and ANA.

### Claim 8 (depends on 1)

The method of claim 1, wherein the human subject has a level of EC4D marker that is less than 6 standard deviations above the mean EC4D marker among non-lupus patients.

### Claim 9 (depends on 1)

The method of claim 1, wherein the human subject has a level of BC4D marker that is less than 6 standard deviations above the mean BC4D marker among non-lupus patients.
